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APPENDIX C 
 
Valorisation 
 
The work for this thesis is the outcome of a multidisciplinary research partnership 
between Maastricht University (Netherlands), GlaxoSmithKline plc (GSK) (United 
Kingdom), Imanova Ltd (United Kingdom) and the Marie Skłodowska-Curie Actions 
Innovative Training Networks (MSCA-ITN) (European Commission). The research 
was performed at the GSK Clinical Imaging Centre and Imanova facilities at the 
Hammersmith Hospital of Imperial College London with the aim of leveraging 
interactions between academia and industry in order to maximize the potential 
valorisation. 
 There is a long history of productive collaboration between biomedical 
researchers in academia and in the pharmaceutical industry. The primary beneficiary 
of this collaboration has been the public, who have benefited from the advances to 
healthcare and quality of life made possible, as well as the jobs creation and economic 
benefits arising from this strong sector of the European economy. Translational 
research interactions with academia have long contributed to the vibrancy of the 
pharmaceutical and related healthcare diagnostics industry. My research, jointly 
supervised by academics and industry mentors, provided an excellent opportunity to 
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contribute to this and to derive considerable personal advantages for development of 
my capabilities. 
The MSCA-ITN programme proved to be an ideal vehicle to overcome and 
cross boundaries in ways that promise to realise future applications of value for the 
healthcare, industry and the general public because of its emphasis on bringing 
stakeholders together for valorisation. In addition, the programme offered high level 
of mobility for the researcher involved and initiatives that support the process of 
strengthening knowledge and the experience. The international aspect of the 
programme made an important contribution to extending the scope of valorisation by 
helping me to better understand how to diffuse the ideas and work in multiple 
countries.  The project implemented the ideas of Marie Skłodowska-Curie, who 
wrote: “I believe that international cooperation is a very difficult task, which has to be 
undertaken, should it even be at the cost of many efforts and true sacrifice”  
Multiple sclerosis is an autoimmune disease of the central nervous system. It 
causes major neurological disability. Currently, there are more than 700,000 people in 
Europe, 100,000 people in the United Kingdom, 46,000 in Spain, 14,000 in 
Netherlands and more than 2 million people throughout the world with this disease. It 
is the most common disabling illness of young adults in the UK and it is twice as 
common in women as in men.  Imaging plays a central role in the diagnosis and 
monitoring of the disease:  the diagnosis made by the neurologists currently is based 
on the so called McDonald’s criteria which allows diagnosis of multiple sclerosis on 
the basis of clinical findings and supported evidence from tests, the most important of 
which are magnetic resonance imaging of the brain and spinal cord. Magnetic 
resonance imaging is used not only to assess the diagnosis, but also to monitor the 
patients during their life.  
135 
 
Conventional imaging has limitations in the evaluation of the causes of 
disability and lacks pathological specificity. My work has further explored an 
advanced method that promises greater sensitivity. Researchers, neurologists and 
neuropathologists can take advantage of new imaging techniques that can overcome 
those limitations. Among them is magnetization transfer, which can give quantitative 
information on the nature of pathological changes and add specificity to diagnostic 
images, thus enhancing assessment of lesion burden and the degree of disability. 
Academia and industry have substantive differences in their approaches, but 
they share the common goal of improving the health of the patients. Industry relies on 
academia for basic research that identifies novel molecular targets, which in turn can 
be used in clinical trials that evaluate the efficacy and safety of derived interventions. 
Industry does not have the vast basic research laboratories and hospitals that exist in 
academia. Conversely, academia is reliant on industry for their discoveries to be 
translated into medicines and technologies used in healthcare. The discovery in the 
present thesis of potential brain and c-spine biomarkers from a novel quantitative MRI 
technique promises to allow future translation from academia to industry and 
healthcare applications. The present thesis invites for testing the proposed 
methodologies on larger groups of patients, after which further technical 
developments of developed technologies may become possible. In addition, the 
discovered biomarkers could be sensitive to other diseases of the central nervous 
system and could be used in other diagnostic studies, focusing perhaps on other 
regions of interest in the brain. In addition, the methods developed here could be 
useful in clinical trials for testing effects of existing and new immunosuppressive 
drugs. 
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 The implementation of the quantitative techniques performed in this thesis can 
be achieved in most of the European biomedical imaging research facilities and 
hospitals of the national health systems using stablished protocols. This provides a 
wide access to a broad established platform and an operational network where the 
derived biomarkers and parameters could contribute to the work of industry 
researchers and clinicians. It has highlighted a research and discovery space in new 
protocols could be developed to generalize the developed technology to ultra- high 
magnetic field technologies, as an attempt to overcome previous limitations, to further 
shed light to the genesis of the microstructural changes of the central nervous system 
tissues involved in neurodegenerative diseases and to create new opportunities for 
value realisation. 
 The pharmaceutical industry lives and breathes translational research. There 
are few organizations on the planet that can do what it has successfully accomplished 
repeatedly: transform knowledge of a potential drug target into a medicine for patients 
around the world. What the pharmaceutical industry does is often referred to as drug 
discovery using a wide bunch of techniques, among them, quantitative MRI. There 
are many opportunities for industry–academia collaborations using the big databases 
that are often collected by pharmaceutical companies (e.g., the GSK-Imperial College 
collaboration). These collaborations using ‘big data’ are expected to become 
increasingly important to achieve progress in the arena of the treatment of both 
neurodevelopmental and neurodegenerative diseases (such as multiple sclerosis). In 
this way, collaboration will spur innovation in the development of new medicines and 
in healthcare delivery. What my thesis work, embedded in an academic programme 
within industry, is that no single sector working alone can bring the needed 
medicines, delivery of care, and infrastructure to prevent and treat diseases of the 
137 
 
world’s population; collaboration between academia and the pharmaceutical industry 
is absolutely necessary and our results can be taken as the outcome of such an 
interaction.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
